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ABSTRACT. 
 
Background: Mycobacterium tuberculosis (MTB) infection remains a serious 
public health challenge in sub-Saharan Africa. Rapid and early diagnosis is critical 
in the successful control of this eminently treatable infection. 
This study compared the diagnostic usefulness of culture,  bone marrow trephine 
biopsy granulomata, bone marrow trephine biopsy Ziehl-Neelsen (ZN) stain and  
bone marrow mycobacterial polymerase chain reaction (PCR) in establishing the 
diagnosis of mycobacterial infection in HIV infected patients. 
 
Materials and methods: The trephine biopsies of HIV positive patients done for 
the investigation of suspected tuberculosis were reviewed for granulomata and 
stained with ZN stain. The corresponding bone marrow aspirates were subjected 
to DNA real-time PCR analyses using LightCyler TB Kit® (Roche Diagnostic). 
Culture results were used as diagnostic gold standard. 
Results:  Of the 60 patients studied, 24 were culture negative. Of the 34 culture 
positive, 62% were Mycobacterium tuberculosis and 38% were Mycobacterium 
avium intracellulare. 
Using the culture method as a gold standard, the sensitivities and specificities 
were 97% and 23% for bone marrow trephine biopsy granulomata, 65% and 58% 
for bone marrow trephine biopsy ZN staining and 50% and 73% for bone marrow 
aspirate PCR analysis respectively. Ninety-seven percent of all trephine biopsies 
with positive ZN stain had granulomata. 
 
 vi
Conclusion: The presence of granulomata in bone marrow trephine biopsies of 
HIV infected patients appear to have a high diagnostic yield whilst mycobacterial 
PCR has the lowest yield but highest specificity. These results should be confirmed 
in a prospective case controlled study because the sample size in this study was 
small, and the study was a retrospective one. 
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CHAPTER 1 
1.1 LITERATURE REVIEW 
1.1.1 Epidemiology of tuberculosis in South Africa 
 
Tuberculosis (TB) is a major public health problem in South Africa, a country  
which is ranked fifth on the list of 22 high-burden TB countries in the world (World 
Health Organisation, 2009). There were  nearly 460,000 new TB cases in South 
Africa in 2007, and the TB infection  incidence rate was  approximately 948 cases 
per 100,000 populations- a major increase from 338 per 100,000  12 years earlier  
in 1998 (World Health Organisation, 2009). The reasons for the high burden of TB 
in South Africa are multi-factorial and some of these are explored in the discussion 
that follows. 
 
1.1.2 Risk factors for tuberculosis 
 
Globally the incidence of TB is increasing, fuelled in part by the concurrent 
epidemic of HIV/AIDS  currently worst affecting sub-Saharan Africa (Harling et al., 
2008). Traditionally TB is regarded as a disease of poverty and many aspects of 
low socioeconomic status for example overcrowding and malnutrition, are 
recognised individual and household level risk factors for the disease (Harling et 
al., 2008). Although for centuries TB has been called the White Plague, in South 
Africa it is predominantly a disease of black Africans, a by-product of poverty, poor 
health care and high HIV infection rate (Koening, 2008). 
 
In the old South Africa, people were previously classified as “coloured” (mixed 
race group), African, white and Asian. TB rates were extremely high in the 
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coloured and African communities compared to whites and Asians, a reflection of 
their poor socioeconomic circumstances (Wood et al., 2000). 
 
A South African population study found that TB was associated with lower 
individual, household and community-level socioeconomic status. Low level of 
personal education, unemployment and a low level of household wealth were 
associated with increased odds of TB (Harling et al., 2008). This analysis found 
alcohol abuse, cigarette smoking and low body mass index (BMI <18.5) each 
independently to be a risk factor for TB in South Africa. 
 
The hypothesis for alcohol consumption and cigarette smoking to be risk factors is 
that in addition to their biological effects, they may be proxies for frequenting 
locations that put one at raised risk of close contact with infectious individuals, 
such as neighbourhood bars (Harling et al., 2008). 
 
The risk factor of developing TB was reported to increase markedly with advanced 
HIV disease; WHO clinical stages 3 and 4 and increased erythrocyte sedimentation 
rate (ESR >75 mm/Hour) were shown to be independently associated with risk of 
developing TB (Wood et al., 2000). 
 
The multidrug-resistant tuberculosis (MDRTB), largely caused by non-adherence to 
drug regimens, is further exacerbating the problem. According to the World Health 
Organisation (WHO) report of 2009, the TB treatment success rate in 2006 was 
67%, with 12% defaulting treatment and 9% failing it. The number of laboratory 
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confirmed cases of MDRTB more than tripled from 2,000 cases in 2005 to 7,350 in 
2007. Among all the new TB cases 1.8% was MDR TB, and among the previously 
treated TB cases MDR TB comprised 6.7%. Since 2007 South Africa has 
increasingly reported patients with extensively drug-resistant tuberculosis (XDR-
TB), and the actual reported cases of XDR-TB had increased from 74 in 2004 to 
536 in 2007 (World Health Organisation, 2009). From 2004-2008 more than 
24,000 cases of MDR TB were diagnosed, of which 7% were infected with XDR TB 
(Kapp, 2009). The combination of drug-resistant TB and HIV infection is especially 
dangerous because the weakened immune systems of HIV-infected persons make 
them more vulnerable to TB and also more difficult to treat (Koening, 2008). 
 
1.1.3 Tuberculosis treatment approaches. 
 
Many South Africans who test positive for TB are started on first-line drugs while 
being investigated for drug resistance (Koening, 2008). XDR TB patients are 
involuntarily isolated or confined to the isolation wards, a move which is 
controversial, but it has to be done as the disease poses an immediate threat to 
public health (Koening, 2008). 
 
South Africa has 100% DOTS (directly observed treatment, short course) 
implementation strategy for TB control. The strategy includes case detection 
through quality assured bacteriology, standardised short course (6-8 months) 
treatment with direct observation of doses to ensure adherence, an effective drug 
supply and management system and monitoring and evaluating, allowing 
assessment of treatment results (World Health Organisation, 2009). 
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Before the implementation of DOTS, TB treatment was in many resource poor 
countries chaotic, non-standardised and poorly monitored and consequently had 
little epidemiological impact on the incidence of TB.  Therefore, the introduction of 
the DOTS strategy has led to improvements in treatment outcomes for many 
patients (Cox and Morrow, 2008). 
 
South Africa adopted the Stop TB Strategy launched by WHO in 2006 (Kapp, 
2009). The core of this strategy is DOTS. It responds to access, equality and 
quality constraints, and adopts evidence-based innovations in engaging with 
private health-care providers, empowering affected people and communities, 
strengthen health systems and promote research (Raviglione and Upleker, 2006). 
 
1.1.4 Epidemiology of HIV in South Africa 
 
An estimated 5.7 million South Africans are HIV-infected (UNAIDS, 2009)  the 
highest infection being reported in KwaZulu-Natal (Koening, 2008). Tables 1.1 and 
1.2 show the prevalence of HIV in South Africa by age, sex, race and province.  
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Table 1.1  HIV prevalence by sex and age in South Africa in 2008 
 
AGE GROUP (YEARS)     HIV PREVALENCE (%) 
 
MALE                              FEMALE 
2-14 3                                       2 
15-19 2.5                                    6.7 
20-24 5.1                                   21.1 
25-29 15.7                                 32.7 
30-34 25.8                                 29.1 
35-39 18.5                                 24.8 
40-44 19.2                                 16.3 
45-49  8.4                                   14.1 
50-54 10.4                                 10.2 
55-59 6.2                                   7.7 
60+ 3.5                                   1.8 
Adapted from Shisana et al., 2009. 
 
Table 1.2  HIV prevalence by sex, age, race and province, South Africa 
2008 
 
Variable HIV+ (%) 95% CI 
Sex   
Male 7.9 6.8-9.2 
Female 13.6 12.5-14.8 
Total 10.9 10.0-11.9 
Age group (years)   
2-14 2.5 1.9-3.5 
15-24 8.7 7.2-10.4 
25+ 16.3 15.3-18.4 
Population group   
African 13.6 12.6-14.8 
White 0.3 0.1-0.9 
Coloured 1.7 1.3-2.4 
Indian 0.3 0.1-1.2 
Province   
Western Cape 3.8 2.7-5.3 
Eastern Cape 9.0 7.2-11.2 
Northern Cape 5.9 4.5-7.8 
Free State 12.6 10.5-15.1 
KwaZulu-Natal 15.8 13.4-18.6 
North West 11.3 9.1-14.0 
Gauteng 10.3 8.3-12.7 
Mpumalanga 15.4 11.9-19.7 
Limpopo 8.8 6.5-11.9 
Adapted from Shisana et al., 2009  
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1.1.5 HIV risk factors 
 
Multiple sexual partners, early sex debut, unprotected sex, intergenerational sex 
(particularly younger females having sex with older males) were shown to 
contribute to the spread of HIV (Katz and Lower-Beer, 2008; Shisana et al., 2009). 
In South Africa, the most at risk populations were shown to include (Shisana et 
al., 2009): 
• African females aged 20-34; 
• African males aged 25-49; 
• Males aged 50+ 
• Men who have sex with men (MSM); and 
• People who use drugs for recreational purposes. 
 
1.1.6 Public health programmes 
 
There are several HIV/AIDS communication and awareness programmes including: 
• The Khomanani “Coming Together” which is a national government 
programme intended for all populations in South Africa; 
• Soul City, a television drama series aimed at educating the public; 
• Soul Buddyz which is intended for children aged 8-12 years; and 
• Lovelife, a youth oriented programme (Shisana et al., 2009). 
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1.1.7 Epidemiology of HIV & TB co-infection 
1.1.7.1 The burden of HIV-TB 
 
Mycobacterial tuberculosis  and atypical mycobacterial infections are very common 
in individuals who are immunocompromised as a result of HIV infection (Karstaedt 
et al., 2001; Sonnenberg et al., 2005). The HIV-TB co-infection rate in South 
Africa was high, and according to WHO report of 2009, an estimated 73% of new 
TB patients were co-infected with HIV. An estimated 31% of all HIV-TB cases in 
Africa were in South Africa.  Mortality rates were 38 and 193 deaths per 100,000 
populations in HIV negative and HIV positive people respectively (World Health 
Organisation, 2009). The HIV and TB co-infection at a public  hospital in 
Johannesburg was found to be 95% (John et al., 2007). 
 
1.1.7.2 Clinical presentation of tuberculosis 
 
From the time of HIV infection, the individual’s susceptibility to tuberculosis is 
increased, and as the HIV epidemic in South Africa progresses, the incidence of 
new cases of TB will continue to increase (Cohen and Maartens, 2004). 
Tuberculosis is often an early manifestation of HIV infection and the pattern of 
clinical presentation depends on the degree of immunosuppression (Charles and 
Pape, 2006; Mwandumba et al., 2008). In the early stages of HIV infection when 
the patients’ immunity is only partially compromised the clinical features are 
characteristic of post-primary TB and resemble those seen in HIV-negative 
individuals such as localised disease with extensive lung destruction and 
cavitation, upper lobe involvement and positive sputum smears (Harries, 1997). As 
the CD4 counts decline, HIV-positive patients present with atypical pulmonary 
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disease (i.e., pulmonary infiltrates with no cavities, lower lobe involvement, 
intrathoracic lymphadenopathy and negative sputum smear) or extra-pulmonary/ 
disseminated disease  affecting many parts of the body such as the lymph nodes, 
abdomen, pericardium and haemopoietic system in the form of bone marrow 
involvement (Harries, 1997; Charles and Pape, 2006; Keshinro and Diul, 2006; 
Mwandumba et al., 2008). 
 
The classic systemic symptoms include fever, night sweats, anorexia, weight loss 
and weakness, however these symptoms are non-specific, sometimes resulting in 
delayed diagnosis or even misdiagnosis (Keshinro and Diul, 2006). 
 
In HIV-positive patients, cough is a symptom reported less frequently than in HIV-
negative patients probably because there is less cavitation, inflammation and 
endotracheal irritation (Harries, 1997).  Similarly, haemoptysis, which results from 
caseous necrosis of the bronchial arteries inside the cavities, is less common in 
HIV-positive patients (Harries, 1997). 
 
1.1.7.3 HIV-TB co-infection treatment approaches & challenges 
 
Antiretroviral (ARV) therapy has been shown to reduce the incidence of TB in HIV-
infected patients by more than 80% (Badri et al., 2002). Both anti-TB treatment 
and ARVs are indispensable in the management of patients with HIV-TB co-
infection (Sharma et al., 2005). The key therapeutic principles underlying the 
treatment of HIV-TB are, (i) treatment of TB always takes precedence over 
treatment of HIV infection, (ii) in patients who are already on ARVs, the same has 
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to be continued with appropriate modifications both in ARVs and anti-TB 
treatment, and (iii) in patients not receiving ARVs, the need for and timing of 
initiation of ARVs have to be decided after assessing the short-term risk of disease 
progression and death, based on CD4 count and type of TB, on individual basis 
(Sharma et al., 2005). 
 
In South Africa, the first-line treatment regimen for ARV-naïve patients in the 
public sector is combination of tenofovir, lamivudine or emtracitabine and 
efavirenz or nevirapine. Patients who fail first line regimen are commenced on 
protease inhibitor (PI)-based second line ARV therapy comprising either tenofovir, 
lamivudine or emtracitabine  and lopinavir/ritonavir or zidovudine, lamivudine and 
lopinavir/ritonavir (South Africa National Department of Health, 2010). The critical 
component of TB treatment is rifampicin and clinically significant pharmacokinetic 
drug interactions exist between standard TB treatment and ARV therapy. 
Rifampicin is a potent inducer of the cytochrome P450 enzyme system, particularly 
the dominant iso-enzyme CYP3A4; rifampicin therefore increases metabolism and 
reduces plasma levels of many hepatically metabolised drugs such as non-
nucleoside reverse transcriptase inhibitors (NNRTIs) and PIs (Cohen and 
Maartens, 2004). 
 
There is an additive risk of side-effects and drug toxicity when ARVs and anti-TB 
drugs are administered together. The common side effects include nausea, 
hepatitis, peripheral neuropathy and rash and these side effects may make 
adherence to treatment difficult (Cohen and Maartens, 2004). Patients with 
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advanced HIV and TB co-infection commonly develop immune reconstitution 
illness when ARVs are commenced (Cohen and Maartens, 2004). 
 
1.1.8 Approaches in tuberculosis diagnosis 
1.1.8.1 Culture of mycobacteria 
 
Blood cultures were not usually processed for the detection of mycobacteria in the 
past and the processing for mycobacteria began with the emergence of HIV-
infected patients  (Martinez-Sanchez et al., 2000). The increasing numbers of 
mycobacterial infections in disseminated forms prompted the searches for rapid, 
sensitive and safe methods for the recovery of mycobacteria from blood (Askgaard 
et al., 1992). 
 
Culture methods have evolved since the advent of HIV, for example in Denmark 
(Askgaard et al., 1992) in early 1980’s coagulated blood and bone marrow 
specimens were inoculated directly on conventional media, that is, Lowenstein-
Jensen media (LJ). Later bone marrow or blood was indirectly inoculated onto 
conventional media or into Bactec 12B media (Becton Dickinson) using the 
Isolator® lysis centrifugation system. This system was based on centrifugal 
concentration of the mycobacteria in a lysing solution containing sodium 
polyanethol sulfonate (SPS) which counteracted phagocytic, lysozymal and 
complement activities in blood. The concentrate was inoculated on LJ media or 
into a 12B vial. The Bactec 12B bottles contained a Middlebrook 7H12 broth 
supplemented with 14C-labelled palmetic acid. The microbial metabolism led to 
release of 14CO2 into the atmosphere above the broth, which was measured by an 
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automated ionisation detector Bactec 460 TB Instrument (Becton Dickinson). The 
amount of 14CO2 was arbitrarily represented as a growth index (GI). 
From 1988 direct inoculation of bone marrow or blood was introduced using 13A 
Bactec vials (Becton Dickinson). These vials were inoculated at the bedside with 
approximately 5 ml of blood or 2 ml of bone marrow. These 13A medium, 
formulated specifically for culturing mycobacterium from blood, was a Middlebrook 
7H9 broth supplemented with casein hydrolysate, Tween 80, SPS and 14C-labeled 
palmitic acid. Upon receipt at the laboratory the 13A vials were supplemented with 
0.5 ml of OADC Enrichment (oleic acid, albumin, dextrose, catalase and sodium 
chloride). The released 14CO2 was measured in the automated Bactec 460 TB 
Instrument. Currently in South Africa the National Health Laboratory Service is 
using Bactec Myco/F lytic blood culture bottles (Becton Dickinson), the Bactec 
9240 Blood Culturing System (Becton Dickinson) and Accuprobe DNA probes 
(Geneprobe) as described in section 2.2.4 in the materials and methods below. 
 
The blood or bone marrow aspirate culture methods are regarded as the gold 
standard for the diagnosis of mycobacterial infection. Blood and bone marrow 
aspirates have been reported to have similar mycobacterial yields (Keiser et al., 
1997; Kilby et al., 1998; Marques et al., 2000; Llewellyn et al., 2005) 
 
Sputum cultures are traditionally carried out in resource-poor countries (Siddiqi et 
al., 2003; Keshinro and Diul, 2006). The sputum culture is much more sensitive 
than routine sputum microscopy as it is able to detect 10-100 AFB per µl (Keshinro 
and Diul, 2006). In high prevalence countries sputum culture can detect 
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pulmonary TB in around 80% of true cases (Siddiqi et al., 2003; Parry, 1993). 
However the sensitivity for  sputum cultures seems to be lower in AIDS patients 
with advanced immune deficiency, due to paucibacillary nature of pulmonary TB in 
these patients (Parry, 1993; Siddiqi et al., 2003; Charles and Pape, 2006). 
 
In terms of specificity, culture methods have the big advantage by allowing 
differentiation between Mycobacterium tuberculosis and other mycobacteria. For 
reference laboratories in high-burden countries, culture methods mainly serve as a 
first step in drug susceptibility testing (DST). DST itself will be reserved to track 
drug resistance. In these laboratories, culture may also enhance research. 
 
The main disadvantage of culture methods is not the need for more sophisticated 
resources and more qualified technicians or higher cost, but its slowness. This is 
certainly so with the classical egg- or agar-based media (Löwenstein-Jensen, 
Ogawa, Middlebrook), for which a positive result requires  3-6 weeks, limiting 
culture methods as the first-line diagnostic tool (Siddiqi et al., 2003; Keshinro and 
Diul, 2006). The delays in the diagnosis lead to delays in treatment initiation; a 
greater number of patients may potentially become infected through contact with 
an infected person (Cobbert et al., 2006). The diagnostic delay of culture, 
together with the presence of advanced disease in many cases at presentation 
and the high index of suspicion among clinicians in countries with a high 
prevalence of TB,  often obliges the clinicians to commence anti-mycobacterial 
therapy based solely on clinical suspicion (Gazzola et al., 2008). 
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The commercial liquid systems (Bactec) may reduce this time by 50% or more, 
but they are more costly and place higher demands on equipment, so that they 
cannot be routinely used in resource-poor countries (Foulds and O'Brien, 1998). 
 
 
1.1.8.2 Sputum smear microscopy 
 
The conventional diagnosis of TB infection relies on sputum smear microscopy for 
acid-fast bacilli (AFB) (Parry, 1993). It is the simplest available diagnostic method 
and has been the mainstay of TB diagnosis for the past 100 years and a key 
technique in the DOTS strategy (Reid and Shah, 2009). Traditionally using direct 
ZN staining of sputum samples, sputum smear microscopy is  highly specific in 
areas  where there is high prevalence of TB, suitable for application in developing 
countries, relatively inexpensive and can be accomplished under field conditions 
(Foulds and O'Brien, 1998; Steingart et al., 2006). 
 
The AFB sputum smear microscopy has a sensitivity of only 50-60% in well-
equipped laboratories staffed with skilled technicians, partly because a positive 
smear requires 5,000-10,000 AFB per µl of sputum sample (Parry, 1993; Siddiqi et 
al., 2003; Charles and Pape, 2006). AFB microscopy detects those cases that are 
epidemiologically most important, i.e., those that are most likely to transmit the 
infection to those in close contacts (Foulds and O'Brien, 1998). Nonetheless, in 
this era of increasing HIV prevalence, the sensitivity of sputum smear microscopy 
is diminished as people who are co-infected with HIV are likely to have smear-
negative pulmonary or extrapulmonary disease (Reid and Shah, 2009).  HIV-
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infected smear-positive patients tend to excrete significantly fewer organisms per 
ml of sputum than HIV-negative patients, which can lead to AFB being missed 
(Harries, 1997; Siddiqi et al., 2003).  
Smear-negative pulmonary TB in HIV/AIDS patients, particularly in low-income 
countries, is a substantial epidemiological problem, accounting for 24-61% of TB 
(Getahun et al., 2007). In areas with high HIV prevalence, smear-negative TB has 
a much worse prognosis (Hargreaves et al., 2001) due in part to delays in 
diagnosis and treatment initiation (Pablos-Mendez et al., 1996). 
 
An alternative to ZN staining of sputum is fluorescence microscopy. It is about 
10% more sensitive than the conventional microscopy and has similar specificity, 
however it is technically complex and costly (Steingart et al., 2006). However a 
Kenyan study found that fluorescence microscopy was more cost effective than 
conventional sputum microscopy and that it shortened the diagnostic process 
(Kivihya-Ndugga, L et al., 2003). Fluorescence microscopy increases the number 
of sputum samples that can be read in a given time, because fewer fields must be 
examined under the microscope, and therefore cost effective than ZN staining 
(Reid and Shah, 2009).   
 
Another method of improving sputum microscopy is the bleach and smear 
method. Sputum is chemically liquefied then concentrated by centrifugation or 
sedimentation. The best established method uses sodium hypochloride (NaOCl), 
the household bleach.  This method has shown greater sensitivity than with ZN 
stain even among HIV positive patients. The main disadvantages of the technique 
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are long processing time and lack of a standardised method (Reid and Shah, 
2009). 
 
AFB sputum microscopy has limited value for diagnosis of TB in children, and does 
not, by definition, identify smear-negative TB, which is more likely in HIV-positive 
patients than HIV-negative individuals (Shingadia and Novelli, 2003; Siddiqi et al., 
2003). 
 
The collection and testing of three consecutive smears (spot-morning-spot) over 2 
days  for TB screening is a matter of contention, especially where prevalence of 
TB is high (Reid and Shah, 2009). Reducing the number of smears- with patient 
giving 2 samples on 1 day rather than three samples over 2 days- could decrease 
the burden on patients and laboratories, and thus improve the sensitivity and 
specificity of direct microscopy (Reid and Shah, 2009). 
Although the chances of finding AFB are greater with three sputum samples than 
with two samples or one (Harries et al., 1996), the incremental yield and 
increased sensitivity gained by examining a third sputum specimen is small (about 
2-5%) (Mase et al., 2007). 
World Health Organisation recently recommended that “the number of specimens 
to be examined to be reduced from 3 to 2 in places where a well-functioning 
external quality assurance (EQA) system exists, where work load is very high and 
human resources are limited” (World Health Organisation, 2007). 
 
 
 16
1.1.8.3 Chest X-ray 
 
X-Ray diagnosis of pulmonary TB is popular with physicians everywhere in the 
world, thanks to its speed, simplicity and ease of use when equipment is available, 
and possibly also because the physician sees it as his tool which he understands 
better (Foulds and O'Brien, 1998). X-Ray has a high sensitivity, and it can detect 
TB in patients who do not excrete any bacilli, however it lacks  specificity (Foulds 
and O'Brien, 1998). Other chest conditions may be accompanied by radiological 
abnormalities misread as TB, especially  for AIDS patients, who may present with 
a variety of upper respiratory illnesses and may be (improperly) treated for TB 
(Foulds and O'Brien, 1998). These conditions include pneumocystis jiroveci 
pneumonia (PCP), pulmonary kaposi’s sarcoma, cryptococcosis and nocadiosis 
(Harries, 1997). In areas with poor diagnostic facilities, it has been suggested that 
more stringent working case definitions be applied to presume pulmonary TB in 
order to assist in differentiating TB from these other conditions (Harries, 1997). 
No radiographic pattern is absolutely diagnostic of TB, although the classical 
hallmarks of the disease are cavitation, apical distribution, bilateral distribution, 
pulmonary fibrosis, shrinkage and calcification (Harries, 1997). Atypical findings 
such as infiltrations without cavitation involving lower lobes and hilar 
lymphadenopathy may also be seen, and are more common in patients with HIV 
infection (Harries, 1997). When the HIV testing was not available or when  
patients refused HIV testing  atypical abnormalities on chest x-ray in patients with 
pulmonary TB  alerted clinicians to the possibility of associated HIV infection 
(Mlika-Cabanne et al., 1995a; Mlika-Cabanne et al., 1995b). Chest radiographic 
manifestations correlate with the degree of immunosuppression (Daley, 1995; 
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Post et al., 1995). Patients with relatively well-preserved immune function will 
show cavitation and upper lobe infiltrates typical of post-primary reactivation in 
immunocompetent patients. Those with severe immunosuppression will show 
changes atypical of primary TB, such as intrathoracic adenopathy and a miliary 
pattern (Daley, 1995). In HIV-positive TB patients in South Africa, the mean CD4 
count was 389x106/l in patients with upper zone infiltration compared with a mean 
CD4 count of 105x106/l in patients with lower or mid-zone infiltrates, adenopathy, 
interstitial pattern or normal radiograph (Post et al., 1995). 
 
1.1.8.4 Extra pulmonary TB (EPTB) 
 
The common forms seen in sub-Saharan Africa, and associated with HIV infection, 
are lymphadenopathy, serous effusions (particularly affecting pleura and 
pericardium) and miliary disease (Harries, 1997). Patients usually present with 
constitutional symptoms: fever, night sweats and weight loss and local features 
related to the site of the disease (Harries, 1997; Keshinro and Diul, 2006). 
Definitive diagnosis of extra pulmonary disease is often difficult in district hospitals 
in Africa, and the degree of diagnostic certainty requires specialised services such 
as histology (Harries, 1997). Bone marrow specimens have been used in the 
diagnosis of extra pulmonary tuberculosis (Bishburg et al., 1986; Askgaard et al., 
1992; Riley et al., 1995; Keiser et al., 1997; Akpek et al., 2001). When the sample 
is a bone marrow trephine biopsy the standard histopathologic approach is to do 
levels through the block to look for histological patterns suggestive of 
mycobacterial infection such as granulomata and to stain the trephine biopsy with 
the Ziehl-Neelsen stain for AFB once granulomata have been identified. This 
 18
approach may be justified as one study reported seeing AFB only in conjunction 
with granulomata, and suggested that it might be unnecessary to use ZN stains if 
no granulomata were seen (Riley et al., 1995). Granulomata are the 
histopathologic hallmark of tissue mycobacterial infection; they represent an 
inflammatory response of an intact immune system to control mycobacterial 
infection (Marques et al., 2000). In the setting of immunodeficiency the presence 
of granulomata has been noted to be less frequent, most likely as a direct 
consequence of impairment of the immune system in this condition (Marques et 
al., 2000). Some studies however found no correlation between the presence of 
granulomata and the detection of mycobacteria, and that stainable organisms 
were found in the absence of granulomata (Bishburg et al., 1986; Marques et al., 
2000). 
 
1.1.8.5 PCR-based genetic tests 
 
Detection is based on multiplication not of whole bacilli, as in culture, but of their 
genetic material, chromosomal DNA or ribosomal RNA. The main advantage of 
PCR-based techniques is their speed of analysis which improves diagnostic 
turnaround time. In principle, only 1-2 days are needed. This is true for diagnosis 
of TB, and even more so for applications such as diagnosis of drug resistance 
(mainly rifampicin) and species identification using probes. This early diagnosis will 
result in early treatment initiation, therefore reducing the potential for the disease 
transmission.  PCR may forego the use of trial of anti-tubercular treatment for 
confirmation of diagnoses. The involvement of the reticuloendothelial system may 
constitute a critical clinical sign of disseminated disease with bacillary load too low 
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to be isolated by conventional culture procedures but detectable by PCR (Singh et 
al., 2006). Conditions such as systemic candidiasis, nocardiosis, cryptococcosis 
that can easily simulate clinical presentation of disseminated tuberculosis can be 
quickly excluded by PCR (Singh et al., 2006). 
 
The main disadvantage of PCR-based tests is their extremely high cost, especially 
when more convenient and more sensitive commercial test kits are available (van 
Cleeff et al., 2005). For resource-poor countries, detection of TB using PCR seems 
unaffordable and perhaps inaccessible.  Even if TB was confirmed in a patient, 
dissemination to the bone marrow may not have occurred at the stage in which 
the sample was collected from the patient (Singh et al., 2006). 
 
A number of different nucleic acid amplification tests for mycobacteria have been 
shown to offer more rapid and potentially highly specific diagnosis. The first PCR 
study was conducted based on DNA coding for 16S rRNA for detection and 
identification of mycobacteria which included M.tuberculosis complex, M.avium, 
M.intracellulare, M.kansasii complex, M.sacrofulaceum, M.xenopi, M.fortuitum and 
M.smegmatis  (Kox et al., 1995). Gamboa et al., (1998) using a ligase chain 
reaction technology, the LCx M.tuberculosis Assay (Abbott Laboratories, 
Diagnostics Division) amplified the chromosomal gene of MTB which codes for 
antigen b which is specific to MTB. 
The PCR amplification of a 316-bp fragment of IS6110 insertion element of MTB 
complex has been reported (Kolk et al., 1998; Ritis et al., 2005). Kivihya-Ndugga 
et al., (2004) used sputum sample and the Amplicor test system (Roche 
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Diagnostics Systems) to amplify a 584-bp ribosomal DNA sequence specific to the 
MTB complex. Using samples such as sputum, skin biopsies, synovial fluid, lymph 
node aspirates, ascitic fluid and bone marrow aspirate the investigators amplified 
the 62kDa gene (165-bp) of MTB with the use of PCR system 2700 thermal cycler 
(Negi et al., 2005). Using bone marrow aspirate samples other investigators 
amplified 240-bp long region of the MPT64 gene for MTB using a thermocycler 
(Singh et al., 2006).  
 
The polymerase chain reaction has been shown to be useful in amplifying 
mycobacterial DNA in pulmonary and extra pulmonary samples. It has been used 
in clinical samples such as sputum, cerebral spinal fluid, pleural effusion, 
peripheral blood and bone marrow aspirates. Bone marrow aspirate has also been 
shown to be a valuable sample and PCR may be useful to identify the 
mycobacterial infection. 
 
South Africa is a middle income nation with a nationally coordinated laboratory 
services that perform among others, culture methods, PCR analysis and 
histological examination of samples. The comparison of these three methods of TB 
diagnosis has not been reported in the setting of high prevalence of HIV-TB co-
infection. We hypothesised that PCR analysis would be highly sensitive and 
specific in the diagnosis of mycobacterial infection from bone marrow samples and 
that the findings would stimulate the roll out of mycobacteria molecular 
diagnostics in South Africa. This might have an impact on costs of TB diagnosis 
and the management of TB in HIV-positive patients in South Africa. Other sub-
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Saharan African countries, unlike South Africa, are resource-poor; the culture 
methods are not readily or routinely available and detection of TB using PCR is 
very unrealistic. The comparison of bone marrow trephine biopsy granulomata and 
bone marrow trephine biopsy Ziehl-Neelsen stain would help assess their 
diagnostic utility, and if highly diagnostic, could be promoted as alternatives in 
these resource-poor countries. 
1.1.9 Aim of the current study 
 
The aim of this study was to compare the diagnostic usefulness of TB culture, 
bone marrow trephine biopsy granulomata, bone marrow trephine biopsy Ziehl-
Neelsen stain and bone marrow aspirate mycobacterial DNA PCR analyses in the 
diagnosis of mycobacterial infection in HIV-positive patients. 
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CHAPTER 2 
2.1 MATERIALS AND METHODS. 
2.1.1 Study design 
 
This was a retrospective, uncontrolled study whereby the haematology laboratory 
bone marrow trephine biopsy registers were reviewed for those trephine biopsies 
which had ZN stain for acid-fast bacilli. These bone marrow trephine biopsies had   
ZN stain if mycobacterial infection was suspected or if bone marrow trephine 
biopsy histological findings were suggestive of mycobacterial infection. Once the 
samples were identified, laboratory records were reviewed on the laboratory 
information system for mycobacterial culture results and CD4 count results of 
samples drawn at around the same time the bone marrow aspirate and trephine 
biopsy were done. The patients who had mycobacterial culture done had their 
CD4 count result, bone marrow trephine biopsy reports and archived unstained 
air-dried bone marrow aspirate smears  retrieved from the laboratory records and 
archive. 
 
The bone marrow trephine biopsy histology reports were reviewed for reported 
presence or absence of granulomata and the results of ZN stain for acid-fast 
bacilli. The bone marrow trephine biopsy’s corresponding unstained bone marrow 
aspirates were retrieved from the archive and were used for deoxyribonucleic acid 
(DNA) extraction for PCR analysis for Mycobacterium tuberculosis, Mycobacterium 
avium intracellulare and Mycobacterium kansasii. 
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2.1.2 Ethical clearance 
 
Permission to use patient materials and laboratory medical records for this study 
was sought from the institutional review committee prior to study initiation. 
Ethics approval was granted by the University of Witwatersrand Human Research 
Ethics Committee. The ethics clearance certificate number is M080618, and it is 
included in appendix A of this research report. 
 
2.1.3 Study population selection 
 
The subjects for this study were patients who presented to the Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH) and Helen Joseph Hospital, which are 
the University of the Witwatersrand Medical Faculty teaching hospitals in 
Johannesburg, between January 2007 and December 2008. 
 
2.1.4 Inclusion criteria. 
 
• Patients who had bone marrow aspiration and trephine biopsy done to 
investigate clinically suspected tuberculosis. 
• HIV positive by any HIV test method. 
• Males and females > 18 years old. 
• Patients who had blood and/or bone marrow aspirate mycobacteria culture 
samples taken around the time bone marrow aspirates and trephine 
biopsies were taken. 
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2.1.5 Exclusion criteria 
 
• Patients who never had blood or bone marrow mycobacteria culture done. 
• Patients with negative or unknown HIV test results. 
• Patients without bone marrow trephine biopsy results. 
The study design is shown in figure 2.1 below. 
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Figure 2.1  Flowchart of the study design 
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2.2.1 DNA extraction 
 
High Pure PCR Template DNA Preparation Kit instructions manual  and the 
National Health Laboratory Service DNA extraction standard operation procedure 
were used for the extraction of the DNA (Roche Applied Science, 2008a; Moodly, 
2009) as shown in figure 2.2. In detail, the unstained air-dried bone marrow 
aspirate smears were washed off the slides using 500µl of the Blood Washer 
(Roche Applied Science, Germany). 
Two hundred microlitres was transferred to 1ml Eppendorf tube (Merck Chemicals, 
South Africa) and the following were added: 
• 200µl of the Binding Buffer (Roche Applied Science, Germany) [6M 
guanidine-HCl, 10mM urea, 10mM Tris-HCl, 20% Triton X-100(v/v), pH 
4.4]. 
• 40µl of reconstituted Proteinase K (Roche Applied Science, Germany) 
which had to be thawed after being stored at -20oC. Proteinase K was 
for sample lysis and inactivation of endogenous DNase. 
• The mixture was vortexed and then incubated at 70oC in a pre-warmed 
heating block for 10 minutes. 
• 100µl of 99% isopropanol (Merck Chemicals, South Africa) was added to 
precipitate the DNA. 
• The sample was pipetted into the upper reservoir of a combined Filter 
Tube-Collection Tube (Roche Applied Science, Germany) assembly. 
• The sample was centrifuged for one minute at 8000g using Eppendorf 
centrifuge 5424 (Merck Chemicals, South Africa). 
• The flowthrough liquid and the collection tube were discarded. 
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• The filter tube was combined with a new collection tube. 
• 500µl of the Inhibitor Removal Buffer (Roche Applied Science, Germany) 
[5 M guanidine-HCl, 20 mM Tris-HCl, pH 6.6] was added to the upper 
reservoir of the sample, followed by centrifugation at 8000g for one 
minute. 
• The flowthrough liquid and the collection tube were discarded, and the 
filter tube was combined with a new collection tube. 
• 500µl of the Wash Buffer (Roche Applied Science, Germany) [20 mM 
NaCl, 2 mM Tris-HCl, pH 7.5] was added to the upper reservoir of the 
sample, followed by centrifugation for one minute at 8000g.This step 
was performed two times. 
• The flowthrough liquid was discarded and the filter tube was combined 
with the same collection tube, and centrifuged at 14000g for 10 seconds 
to remove the Wash Buffer. 
• The collection tube was discarded and the filter tube was inserted into a 
sterile 1.5 ml microfuge tube (Roche Applied Science, Germany). 
• 100µl of pre-warmed (70oC) Elution Buffer [10 mM Tris-HCl, pH 8.5] 
(Roche Applied Science, Germany) was added to the tube, followed by 
centrifugation at 8000g for one minute. 
• The microfuge tube with the eluted DNA was stored at -20oC until PCR 
analysis was performed. 
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200 µl bone marrow 
aspirate
Add 100 µl isopropanol, mix well and 
apply mixture to High Pure filter tube, 
centrifuge for 1 minute at 8,000 x g
Centrifuge for 1 minute 
at 8,000 x g
Centrifuge for 1 minute 
at 8,000 x g
Centrifuge for 1 minute 
at 8,000 x g
Centrifuge for 10 
seconds at 14,000  x g
Centrifuge for 1 minute 
at 8,000 x g
Purified Template DNA
Add 200 µl Binding 
Buffer and 40 µl 
Proteinase K, mix 
immediately, 
incubate for 10 
minutes at 70°C 
Discard flowthrough 
and collection tube
Discard flowthrough 
and collection tube
Discard flowthrough 
and collection tube
Discard flowthrough
Discard  collection 
tube
Add 500 µl 
Inhibitor Removal 
Buffer
Add 500 µl Wash 
Buffer
Add 500 µl Wash 
Buffer
Add new tube 
and 100 µl 
Elution Buffer 
(70°C)
 
Figure 2. 2  Flowchart of manual DNA extraction  
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2.2.2 DNA quantification 
 
DNA concentration was measured using NanoDrop® ND-1000 Spectrophotometer 
according to the manufacturer’s manual (NanoDrop Technologies, 2006) and the 
National Health Laboratory Service standard operating procedure (Instrument 
Working Group, 2009). This instrument is a full-spectrum (220-750nm) 
spectrophotometer that utilised patented sample retention technology that 
employed surface tension alone to hold the sample in place. No cuvettes and 
other sample containment devices were required. It measured the concentration 
in nanogram per microlitre (ng/µl) based on absorbance at 260 nm and the 
selected analysis constant. The concentration was calculated using Beer’s Law. 
The instrument has the capability to measure highly concentrated samples without 
dilution. Its detection limit is 2 ng/µl and has upper limit of detection of 3700 
ng/µl of double stranded DNA. No reagents were required. 
 
 A 1µl DNA solution from stored sample was pipetted onto the end of a fibre optic 
cable (the receiving fibre). A second fibre optic cable (the source fibre) was 
brought into contact with the liquid sample causing the liquid to bridge the gap 
between the fibre optic ends. A pulsed xenon flash lamp provided the light source 
and a spectrometer utilising a linear charge-coupled device (CCD) array was used 
to analyse the light after passing through the sample. When analysis was 
complete, the DNA concentration was displayed on the instrument’s screen. 
Before the samples were loaded onto the instrument, a blanking cycle using 
distilled water was performed. This was to ensure that the instrument was 
working well and that there was no non-specific fluorescence evidenced by a 
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spectrum with a relatively flat baseline. Upon completion of each sample 
measurement, both the receiving fibre and the source fibre were wiped using soft 
laboratory wipes to prevent sample carryover. The instrument required no 
calibration as the wavelength was auto calibrated based on known peaks in the 
xenon lamp spectra each time the software was started. 
 
2.2.3 Amplification of mycobacterial DNA by PCR. 
 
 PCR detection was based on multiplication not of whole bacilli, as in culture, but 
of their genetic material, namely, chromosomal DNA. LightCycler TB Kit® for the 
detection of Mycobacterium tuberculosis, Mycobacterium avium and 
Mycobacterium kansasii  and LightCycler® Mycobacterium Detection Kit (Roche 
Applied Science, 2008b; Roche Applied Science, 2008c)  were used for 
mycobacterial DNA polymerase chain reaction. 
 
An approximately 200 base pair fragment was amplified from isolated 
mycobacterium DNA using specific primers. The oligonucleotide primers bound a 
portion of the 16S rRNA gene that included the hyper variable region A of the 
mycobacterium. The amplicon was detected by fluorescence using a specific pair 
of HybProbe probes. These probes consisted of two different oligonucleotide 
sequences that hybridised to an internal sequence of the amplified fragment 
during the annealing phase of the PCR cycle. One probe was labelled at the 5’-end 
with LightCycler® Red 640 fluorophore and was phosphorylated at the 3’-end to 
avoid extension. The other probe was labelled at the 3’-end with flourescein. After 
hybridisation to the template DNA, the two probes came in close proximity, 
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resulting in fluorescence resonance energy transfer (FRET) between the 
fluorophores. The emitted fluorescence for the amplicon was detected using 
LightCycler® Red 640. A synthetic internal control was detected using HybProbe 
probes labelled with LightCycler® Red 705. 
 
Real Time Polymerase Chain Reaction LightCycler® 1.5 (Roche Applied Science, 
Germany) instrument was used for the PCR. The PCR kits,  that is, the LightCycler 
TB Kit® and the LightCycler® Mycobacterium Detection Kit comprised the 
following: enzyme, reaction mix, PCR grade H20, detection mix, positive control, 
negative control, internal control and uracil-DNA glycosylate. LightCycler TB Kit® 
did not contain uracil-DNA glycosylate. 
Additional equipment and reagents required included: 
• Ultra violet dead-air box cabinet (locally made by the NHLS maintenance 
department). 
• LightCycler capillaries (Roche Applied Science, Germany). 
• LightCycler capping tool (Roche Applied Science, Germany). 
• Eppendorf (Merck Chemicals, South Africa) bench top micro centrifuge. 
• LightCycler carousel (Roche Applied Science, Germany) which provided 
centrifuge adapters that enabled the LightCycler capillaries to be 
centrifuged in a standard micro centrifuge rotor. 
• 10, 100, 1,000 µl Finnitip® pipettes (AEC Amersham, South Africa). 
• Nuclease-free, aerosol-resistant pipette tips (10 µl tips were supplied by 
AEC Amersham, South Africa; and the 50, 200, 1000 µl tips were 
supplied by Whitehead Scientific, South Africa). 
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• Sterile reaction (Eppendorf) tubes for preparing master mixes and 
dilutions. 
• Gloves (Kendon Medical Supplies, South Africa). 
• Marker pen for labelling tubes. 
• Bleach (NHLS Diagnostic Media Products, Johannesburg) and ethanol 
(Merck Chemicals, South Africa) in spray bottles for cleaning the UV 
cabinet. 
• Standard fridge with freezer. 
• LightCycler capillary releaser (Roche Applied Science, Germany) 
• Sharps bin, for used LightCycler capillaries. 
Unfortunately Roche, South Africa, due to patency secrecy, could not disclose the 
sequences of the primers, the detection mix nor the compositions of the internal 
controls, negative controls, positive controls, the enzymes and the reaction mix. 
2.2.3.1 PCR set up. 
 
The PCR preparation mixes are shown in tables 2.1 and 2.2. 
 
Table 2.1  PCR mix preparation for LightCycler TB Kit®  
 
Component Volume for one 
reaction 
LCTB MMX (pink) 11 µl 
Master Mix (vial 1) 4 µl 
Internal Control 1 µl 
Total reagent mix 16 µl 
LCTB MMX = LightCycler TB detection mix 
Master Mix = Enzyme + Reaction mix 
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Table 2.2  PCR mix preparation for LightCycler® Mycobacterium  
Detection Kit 
 
Component Volume for one 
reaction 
Detection Mix (vial 3) 11 µl 
Master Mix (vial 1) 4 µl 
Internal Control (vial 6) 0.75 µl 
Uracil-DNA Glycosylase (vial 7) 0.25 µl 
Total reagent mix 16 µl 
 
LightCycler® capillaries were placed in pre-cooled centrifuge adapters. The 
reagent mix was carefully mixed by pipetting up and down, and then 16 µl of 
reagent mix was pipetted into each capillary. 
Four micro litres of each patient sample was added to its respective capillary tube. 
Four microlitres each of a positive and a negative control were added to separate 
capillary tubes. The capillary tubes were sealed with stoppers then centrifuged at 
3000 revolutions per minute for five seconds. The PCR was run under the 
following conditions: 
• Denaturation at 95oC for 600 seconds. 
• Amplification: 45 cycles at 95oC for 10 seconds, 50oC for 10 seconds 
and 72oC for 20 seconds. 
• Melting curve: 1 cycle at 95oC for 60 seconds, 40oC for 120 seconds 
and 68oC for zero seconds. 
• Cooling: 1 cycle at 40oC for 30 seconds. 
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2.2.3.2 PCR Data interpretation 
 
Colour compensation file was required for analysis of data. Manual melting 
temperature (Tm) was used to analyse the results. Mycobacteria species were 
viewed in channel 640, and the Internal Control was viewed in channel 705. 
If the positive control and/or the negative control failed, the entire run was 
considered invalid and had to be repeated. For the valid run the control results 
were interpreted according to the table 2.3 below: 
Table 2.3  Interpretation of a valid run 
 
Mycobacterium 
 (channel 640) 
Internal Control 
(channel 705) 
Result interpretation 
Positive Positive Positive 
Negative Positive Negative 
Positive Negative Positive 
Negative Negative Invalid result 
 
Positive control PCR (channel 640) showed a single melting peak with a Tm value 
of 58.1 ± 1.5oC (figure 3.2). The negative control always showed no signal in 
channel 640, but it showed a Tm of 63.1 ± 1.5oC in channel 705 (figure 3.4). The 
Mycobacteria species were viewed in channel 640 and their melting temperature 
ranges are shown in table 2.4 
Table 2.4  Result interpretation 
 
Organism Mean Tm (oC) 
Mycobacterium tuberculosis 55-57 ± 1.5 
Mycobacterium kansasii 59-62 ± 1.5 
Mycobacterium avium 50-53 ± 1.5 
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2.2.4 Mycobacterial culture 
 
The cultures were done at NHLS Mycobacterial Referral Laboratory, Johannesburg 
as per standard operating procedures  (Rautenbach, 2008; TB Laboratory Working 
Group, 2008; Dolby, 2009). 
Bactec Myco/F lytic blood culture bottles (Becton Dickinson, USA), the Bactec 9240 
Blood Culture System (Becton Dickinson, USA) and Accuprobe DNA probes 
(GeneProbe, USA) for mycobacteria identification were used. Other equipment and 
materials required were: 
• Lowenstein Jensen Media (LJ) (NHLS Diagnostic Media Product, 
Johannesburg) 
• Syringes and needles, 
• Light microscope, 
• Microscope slides, 
• Stains, and 
• Aerobic incubator. 
 
Five millilitres of blood or bone marrow specimen were collected by hospital staff 
and inoculated into the Bactec Myco/F lytic blood culture bottles (Becton 
Dickinson, USA). These bottles contained Middlebrook 7H9 and brain heart 
infusion broth formulation for the recovery of mycobacteria. Specific modifications 
were made to enhance the growth and recovery of mycobacteria. These 
modifications included ferric ammonium citrate to provide iron source for specific 
strands of mycobacteria. Other supplements included saponines (blood lysing 
agent), anticoagulants and specific proteins and sugars to provide nutritional 
supplements.  
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The culture bottles were placed in the Bactec 9240 Blood Culture System (Becton 
Dickinson, USA) a continuous-monitoring blood culture system. Each culture bottle 
contained a sensor which could detect decreases in oxygen concentration resulting 
from micro organism metabolism and growth. The sensor was monitored by the 
Bactec Blood Culture System for increasing fluorescence which was proportional to 
the decrease in oxygen. A positive determination indicated the presumptive 
presence of micro organisms in the bottle. 
The culture bottles that were positive were processed as follows: 
• A smear was prepared and a Ziehl-Neelsen stain (NHLS Diagnostic Media 
Products, Johannesburg) was performed to establish the presence and 
morphology of the acid-fast bacilli. 
• Depending on the morphology of the micro organisms, the following 
detection kits were used for species identification: Accuprobe 
Mycobacterium Tuberculosis Complex Culture Identification test 
(GeneProbe, USA), Accuprobe Mycobacterium Avium Complex Identification 
test (GeneProbe, USA) and Accuprobe Mycobacterium Kansasii 
Identification test (GeneProbe, USA). 
Positive and negative controls were used routinely in the Accuprobe tests. The 
choice of Accuprobes used depended on the morphology of the organism seen on 
Ziehl-Neelsen stain. If, for example, the morphology suggested mycobacterium 
tuberculosis, mycobacterium tuberculosis was used as a positive control and 
mycobacterium kansasii was used as a negative control. 
The Accuprobe mycobacterial identification test was a rapid DNA probes that 
utilised the technique of nucleic acid hybridisation for the identification of 
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mycobacterium. A single strand DNA probe with a chemiluminescent label that 
was complimentary to the ribosomal RNA of the target organism, combined to 
form a stable DNA: RNA hybrid, which was measured using a luminometer. The 
luminometer was interpreted as follows: 
 Cut-off range: 30,000 RLU. 
Repeat range: 20,000-29,999 RLU 
Negative        < 10,000 RLU 
Positive          > 30,000 RLU. 
 
If the culture bottles were positive but no mycobacteria were observed on stain, a 
subculture was made onto LJ medium for 6 weeks, and read every week. If 
positive mycobacteria identification was done, the species were identified using 
the Accuprobes. If negative after 6 weeks, the sample was reported as no growth. 
 
2.2.5 Bone marrow trephine biopsy histological preparation 
 
Bone marrow trephine biopsy histological preparation was done in the 
Histopathology Department of the National Health Laboratory Service Charlotte 
Maxeke Johannesburg Academic Hospital as per tissue processing standard 
operating procedure (Anatomical Pathology Working Group, 2007). The trephine 
biopsies were fixed in a neutral buffered formalin (Barr Pharmaceuticals) once 
obtained from the patients. When the trephine biopsies were received in the 
Histopathology department they were further fixed for 24 hours in 10% formalin 
(Merck Chemicals, South Africa) and then placed in cassettes. They were then 
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softened in ethylenediaminetetraacetic acid (EDTA) for 24-48 hours. The following 
steps were then done: 
 2.2.5.1 Processing 
 
Equipment Tissue-Tek® VIPTM (Siemens, Southern Africa) was used to process the 
trephine biopsies. The whole process included immersion of trephine biopsies into 
different concentrations of formalin, then alcohol followed by the clearing agent 
and wax impregnation. 
In detail there were 14 stages. Stages 1 and 2 involved the immersion of the 
trephine biopsy in 10% formalin for 2.5 hours per each stage. Stage 3 involved 
the immersion of the trephine biopsy in 80% alcohol (SMM Instruments, South 
Africa) for 30 minutes. In stages 4 and 5 the trephine biopsy was immersed in 
95% alcohol (SMM instruments, South Africa) for 30 minutes per stage. In stages 
6, 7, and 8 the trephine biopsy was immersed in absolute alcohol (SMM 
Instruments, South Africa) for 30 minutes, 30 minutes and 40 minutes 
respectively. In stages 9 and 10 the samples were immersed in xylene (Merck 
Chemicals, South Africa) for 30 and 40 minutes respectively. Stages 1 to 10 were 
performed at 400C. Stages 11 to 14 were performed at 600C and all involved 
immersion of the trephine biopsy in wax (Siemens, Southern Africa) for 30 
minutes per stage. 
 
 2.2.5.2 Embedding 
 
Tissue-Tek® TECTM (Siemens, Southern Africa) was used. Hot wax was put onto 
the sample cassettes followed by cooling. 
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2.2.5.3 Cutting 
 
Microtome was used to cut the embedded trephine biopsy. The cut sections were 
placed onto the glass slides and then floated in 40-50oC water bath for the 
sections to stretch. The slides were then put on a 50oC hot plate for at least 15 
minutes to allow the sectioned trephine biopsies to adhere to the glass slides. 
 
2.2.5.4 Final step 
 
The trephine biopsies were immersed in xylene, then 100% alcohol followed by 
95% alcohol to dehydrate the trephine biopsies. They were then washed in tap 
water. 
The trephine biopsies were then ready for haematoxylin and eosin (HE) stain and 
the Ziehl-Neelsen stain. 
 
2.2.6 Haematoxylin and eosin stain 
 
The bone marrow trephine biopsies were stained with haematoxylin stain (Merck 
Chemicals, South Africa) for 10 minutes and then rinsed with tap water to remove 
excess haematoxylin. The trephine biopsies were then immersed in Scott’s water 
(Merck Chemicals, South Africa) for 1 minute to make the nuclei blue, and then 
they were washed in tap water. They were stained with eosin (Merck Chemicals, 
South Africa) for 5 minutes and then washed in tap water to remove excess eosin. 
They were then immersed in 3 basins of 100% alcohol each to dehydrate the 
samples, followed by 2 basins of xylene to clear the sections. The cover slips were 
put onto the slides to protect the trephine biopsies from scratches and drying out. 
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2.2.7 Ziehl-Neelsen stain. 
 
Ziehl-Neelsen stain (NHLS Diagnostic Media Products, Johannesburg) for 
demonstration of acid fast bacilli was done in the NHLS Histopathology 
Department at the CMJAH as per currently used standard operating procedure 
(Anatomical Pathology Working Group, 2009). The trephine biopsies were stained 
with filtered carbol fuschin for 5 minutes and then rinsed in tap water. Ninety-five 
percent alcohol was used to rinse the trephine biopsies to remove the excess 
carbol fuschin followed by tap water rinsing. Seventy percent acid alcohol was 
used for differentiation until the sections were pale blue followed by rinsing in tap 
water. Methylene blue was added to the trephine biopsies for counter staining for 
1-2 minutes followed by rinsing in tap water. The trephine biopsies were then 
dried by air or by blotting. Cover slips were mounted onto the slides. Ziehl-Neelsen 
stain was always done with a known ZN positive section as a control to control for 
staining and procedural artefacts. 
2.3 STATISTICAL ANALYSIS. 
 
All results were tabulated in Microsoft Excel® spread sheets. Mycobacterial culture 
was considered the gold standard for the diagnosis of mycobacterial infection in 
this study. A 2 X 2 contingency table was constructed to calculate sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV) for 
each of the three diagnostic methods. 
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 CHAPTER 3 
3.1 RESULTS 
3.1.1 Study population 
 
A total of seventy patients were reviewed and assigned study numbers 1 to 70. 
Ten patients (study numbers 25, 26, 27, 37, 53, 54, 55, 61, 68 and 69) were 
excluded from the study due to lack of complete data such as HIV status and /or 
incomplete culture results. Sixty patients met the inclusion criteria and were 
therefore included in the study. These patients presented to Charlotte Maxeke 
Johannesburg Academic Hospital and Helen Joseph Hospital with clinical suspicion 
of mycobacterial infection. 
In the eligible study population of 60 patients, females comprised 31 subjects 
(51%)   and males comprised 29 subjects (49%). The mean age was 35.5 years 
(range 21-55 years) as shown in table 3.1. The study population laboratory 
findings, that is, the culture results, bone marrow trephine biopsy ZN stain, CD4 
count, mycobacterial DNA PCR result and bone marrow trephine biopsy 
histological findings, are shown in the table 3.2  
 
 
 
 
 
 
 
 
 
 
 
 42
Table 3. 1 Demographics of the study population 
 
Study  
Number 
 
Age 
(years) 
Sex 
34 35 F 
35 24 F 
36 36 F 
38 36 F 
39 32 M 
40 37 F 
41 31 M 
42 44 M 
43 34 F 
44 35 F 
45 36 F 
46 34 M 
47 39 M 
48 29 F 
49 37 F 
50 41 M 
51 25 M 
52 37 M 
56 29 F 
57 55 M 
58 45 M 
59 30 F 
60 23 M 
62 33 M 
63 45 M 
64 24 M 
65 25 F 
66 51 M 
67 21 F 
70 35 F 
 
M = Male; F = Female 
Number of patients screened= 70 
Number of patients eligible for study = 60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study  
Number  
Age 
(years) 
Sex 
1 47 F 
2 40 F 
3 32 F 
4 39 M 
5 25 M 
6 33 F 
7 49 M 
8 38 F 
9 29 F 
10 39 F 
11 42 M 
12 32 M 
13 27 F 
14 29 M 
15 47 M 
16 40 M 
17 40 M 
18 30 F 
19 40 F 
20 40 F 
21 49 M 
22 30 M 
23 44 F 
24 31 M 
28 31 F 
29 40 M 
30 54 F 
31 30 M 
32 28 F 
33 22 F 
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Table 3. 2 Study population culture, trephine, CD4 and PCR results  
 
Study 
number 
Culture ZN 
stain 
Granu 
loma 
CD4 
Count 
(X106/l) 
PCR 
34 MTB + + 9 - 
35 MTB + + 0 MTB 
36 MA + + 40 - 
38 MTB + + ND MTB 
39 MTB + + 31 - 
40 MTB - + 4 - 
41 MA - + 8 MA 
42 MTB + + 18 - 
43 MA + + 73 MA 
44 MTB + + 20 MTB 
45 MTB - + 848 - 
46 MTB - + 9 - 
47 MA + + 0 MA 
48 MA + + 0 MA 
49 MA + + 31 MA 
50 MA - + 34 MA 
51 MTB - + ND - 
52 MA + + 1 MA 
56 MTB + + 24 MTB 
57 MTB - + 18 - 
58 MA + + ND - 
59 MA + + 2 MA 
60 MTB + + 2 MTB 
62 MTB - + 23 - 
63 - - + 3 - 
64 - + + 67 - 
65 - + + 136 MTB 
66 - - + 207 - 
67 - - - 13 - 
70 - + + 14 MTB 
 
 
MA = Mycobacterium avium                                - = Negative 
MTB = Mycobacterium tuberculosis                     + = Positive 
MK = Mycobacterium kansasii                           ND = Not done  
 
 
 
 
Study 
number 
Culture ZN 
stain 
Granu 
loma 
CD4 
Count 
(X106/l) 
PCR 
 1 - - - 127 - 
2 - - + 7 MTB 
3 - - - ND - 
4 - - + ND - 
5 - + + ND - 
6 - + - 6 - 
7 - - - 42 - 
8 - - + 375 - 
9 - - + 70 - 
10 - - + 194 - 
11 - + + 33 MTB 
12 - + + 57 MTB 
13 - - + 146 MK 
14 - - + 98 - 
15 - - + 196 - 
16 - + + 22 MTB 
17 - + + 62 - 
18 - + + 21 - 
19 - - - 21 - 
20 - + + 14 - 
21 MTB - + 65 - 
22 MTB + + 89 - 
23 MTB + + 2 - 
24 MA + + 7 MK 
28 MA - - 8 - 
29 MTB - + 32 - 
30 MTB + + 14 MTB 
31 MTB - + 40 - 
32 MA + + 32 MTB 
33 MTB + + 37 MTB 
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3.1.2 Mycobacterial culture 
 
In the presence of adequate controls, 34 out of 60 patients analysed had positive 
mycobacterial culture results (study numbers 21-24, 28-36, 38-52, 56-60 and 62)  
and 26 out of 60 were mycobacterial culture negative  (study numbers 1-20, 63-
67 and 70). The following culture negative patients: study numbers 1, 14, 15, 63, 
64, 65 and 66 were on anti-tuberculosis therapy for unspecified duration at the 
time the samples were collected for analysis. 
Of the 34 positive culture results, 21 (62%) were Mycobacterium tuberculosis and 
13 (38%) were mycobacterium avium. There was no mycobacterium kansasii 
detected on culture methods in this study population.  
 
Of the 26 culture negative patients, 5 patients (patient study numbers 11, 12, 16, 
63 and 70) showed positivity for granulomata, ZN staining and PCR for MTB. 
Further 4 patients (patient study number 5, 17, 18 and 64) showed positivity for 
granulomata and ZN staining. 
 
3.1.3 Bone marrow trephine biopsy granulomata 
 
Out of the 34 patients with positive mycobacterial culture, 33 patients (97%) had 
granulomata present in their bone marrow trephine biopsies and only 1 (3%) had 
no granulomata present. 
Out of 26 mycobacterial culture negative patients, 20 (77%) had granulomata in 
their bone marrow trephine biopsies, and 6 (23%) did not have granulomata. 
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3.1.4 Bone marrow trephine biopsy Ziehl-Neelsen (ZN) stain 
 
In the presence of adequate ZN positive controls, 22 of 34 (65%) culture positive 
patients had positive ZN stain on their bone marrow trephine biopsies while 12 out 
of 34 (35%) were negative for ZN stain. Fifteen of 26 (58%) culture negative 
patients had negative ZN stain on their bone marrow trephine biopsies. Five of 
these 15 patients were on anti-tuberculosis therapy at the time of specimen 
collection. Eleven of 26 (42%) culture negative patients stained positive for ZN 
stain on bone marrow trephine biopsies. Two of these 11 patients were on anti-
tuberculosis therapy. 
 
3.1.5 Bone marrow trephine biopsy Ziehl-Neelsen stain and bone 
marrow trephine biopsy granulomata 
 
Thirty-three patients had positive bone marrow trephine biopsy Ziehl-Neelsen 
stain; 32 (97%) of which had granulomata in their bone marrow trephine biopsies. 
 Using ZN stain as standard, granulomata showed a sensitivity and a specificity of 
97% and 22% respectively. 
3.1.6 CD4 count 
 
Six patients did not have their CD4 count done. The mean CD4 count for 54 
patients was 67.7x106/l (range 0-848x106/l). 
Out of 34 culture positive patients 31 had CD4 count done, and their mean CD4 
count was 49x106/l (range 0-848x106/l). The patients diagnosed with 
Mycobacterium avium intracellulare on culture had a mean CD4 count of 
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19.7x106/l (range 0-73x106/l). The patients who were diagnosed with 
Mycobacterium tuberculosis had a mean CD4 count of 67.6x106/l (range 0-
848x106/l). 
Out of 26 culture negative patients 23 had CD4 count done and their mean CD4 
count was 84x106/l (range 3-375x106/l. 
3.1.7 DNA extraction 
 
DNA was extracted from 70 patients ten of which (study numbers 25, 26, 27, 37, 
53, 54, 55, 61, 68 and 69) were excluded. Sixty met inclusion criteria and their 
DNA concentration is shown in table 3.3. 
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Table 3. 3  Patient DNA concentration  
 
Study number DNA  
concentration  
(ng/µl) 
34 7.2 
35 3.0 
36 190.6 
38 43.8 
39 29.7 
40 12.7 
41 140.9 
42 15.0 
43 128.8 
44 26.8 
45 188.0 
46 22.2 
47 2.7 
48 4.6 
49 3.1 
50 2.5 
51 2.7 
52 73.0 
56 16.5 
57 27.7 
58 22.3 
59 106.4 
60 141.8 
62 201.5 
63 7.3 
64 6.7 
65 42.8 
66 10.1 
67 41.4 
70 12.0 
ng/µl = nanogram per microlitre. 
3.1.8 Mycobacterial DNA PCR 
 
Mycobacterial DNA PCR analysis was performed on bone marrow aspirates from all 
60 patients as described above. For all PCR runs the positive controls and negative 
Study number DNA  
concentration  
(ng/µl) 
1 43.1 
2 242.5 
3 19.5 
4 49.5 
5 8.4 
6 7.3 
7 10.2 
8 14.5 
9 201.6 
10 40.5 
11 13.3 
12 38.8 
13 20.8 
14 91.5 
15 23.2 
16 115.0 
17 210.0 
18 18.3 
19 24.0 
20 8.1 
21 175.1 
22 46.9 
23 5.8 
24 15.7 
28 12.7 
29 176.0 
30 26.3 
31 28.3 
32 136.6 
33 203.3 
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controls were successful as shown in figures 3.1 and 3.2. The Internal Control was 
added to positive control, negative control and the study samples, and co-
amplification of the internal control is shown in figures 3.3 and 3.4. 
 In the presence of adequate positive and negative controls 17 of the 34 (50%) 
mycobacterial culture positive patients yielded positive mycobacterial DNA on PCR. 
A typical positive PCR is shown as a green curve in figures 3.1 and 3.2.  
The mycobacterial culture result of patient study number 24 yielded 
Mycobacterium avium, but the mycobacterial DNA PCR analysis yielded 
Mycobacterium kansasii. Mycobacterial culture for patient number 32 yielded 
Mycobacterium avium but the DNA PCR yielded Mycobacterium tuberculosis (table 
3.2) 
Out of 26 mycobacterial culture negative patients, mycobacterial DNA was 
amplified in 7 samples (23%); and 19 samples (73%) were negative on PCR. A 
typical negative PCR result is shown as a pink flat curve/ line in figures 3.1 and 
3.2. 
Out of 24 mycobacterial DNA PCR positives 14 (58.3%) were Mycobacterium 
tuberculosis, 8 (33.3%) were Mycobacterium avium intracellulare and 2 (8.3%) 
were Mycobacterium kansasii. The mycobacteria subtypes were differentiated by 
their melting temperatures (Tm) as shown in figure 3.2 (red for MA with Tm of 
49.10C and green for MTB with Tm of 55.30C). 
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Figure 3.1  Target amplification curves for controls and representative 
patients 
  
                   Positive Control 
 
     Study number 48: Mycobacterium avium intracellulare 
 
      Study number 56: Mycobacterium tuberculosis 
 
  Negative Control 
  
                  Study number 62: No amplification 
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Figure 3.2  Target melting curves and melting peaks for controls and 
representative patients 
 
                   Positive Control 
 
     Study number 48: Mycobacterium avium intracellulare 
 
      Study number 56: Mycobacterium tuberculosis 
 
  Negative Control 
  
                  Study number 62: No amplification 
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Figure 3.3  Internal Control amplification curves 
 
  
                   Positive Control 
 
     Study number 48 
 
      Study number 56 
 
  Negative Control 
  
                  Study number 62 
 
 
 
 
 
 52
 
Figure 3.4  Internal Control melting curves and melting peaks 
 
  
                   Positive Control 
 
     Study number 48 
 
      Study number 56 
 
  Negative Control 
  
                  Study number 62 
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3.1.9 Statistical comparison of different methods 
 
The sensitivity, specificity, positive predictive value and negative predictive value 
of each diagnostic method were calculated using culture method as gold standard 
and the results are shown in table 3.4. 
 
Table 3. 4  Comparison of the three diagnostic method results using 
mycobacterial culture as gold standard 
 
Diagnostic 
method 
Sensitivity 
% 
Specificity 
% 
Positive 
predictive 
value % 
Negative 
predictive 
value % 
Mycobacterial 
DNA PCR 
50 73 71 53 
Bone marrow 
trephine 
biopsy 
granulomata 
97 23 62 86 
Bone marrow 
trephine 
biopsy Ziehl-
Neelsen stain 
65 58 67 56 
 
Sensitivity refers to how good a test is at correctly identifying people who have 
the disease. It is calculated by dividing the number of true positives (TP) by the 
sum of true positives (TP) and false negatives (FN) (Loong, 2003).  
[Sensitivity= TP ̸ TP+FN]. 
True positives are defined as sick people correctly identified as sick, and false 
negatives as sick people incorrectly identified as healthy (Loong, 2003).  
Specificity refers to how good the test is at correctly identifying people who are 
well. It is calculated by dividing true negatives (TN) by sum of true negatives (TN) 
and false positives (FP) (Loong, 2003). [Specificity= TN ̸ TN+FP]. 
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True negatives are defined as healthy people correctly identified as healthy and 
false positives as healthy people incorrectly identified as sick (Loong, 2003).  
 
Positive predictive value (PPV) is the proportion of patients with positive test 
results who are correctly diagnosed. It is calculated as follows: (Altman and Bland, 
1994; Loong, 2003) 
PPV= TP/ TP + FP, or 
(Sensitivity)(Prevalence)/(sensitivity) (prevalence) + (1-specificity) (1-prevalence). 
 
Negative predictive value (NPV) is the proportion of patients with negative results 
who are correctly diagnosed. It is calculated as follows: (Altman and Bland, 1994; 
Loong, 2003) 
NPV= TN/ TN+FN, or 
(Specificity)(1-prevalence)/(specificity)(1-prevalence)+(1-sensitivity) (prevalence). 
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 CHAPTER 4 
4.1 DISCUSSION 
4.1.1 Mycobacterial Culture 
 
No test is considered the gold standard for the diagnosis of mycobacterial infection 
(Escobedo-Jaimes et al., 2003). This study however regarded the culture method 
as a gold standard against which other methods were compared. No distinction 
was made between bone marrow aspirate cultures and blood cultures as these 
two methods have been shown previously  to have similar mycobacterial 
diagnostic yields (Riley et al., 1995; Kilby et al., 1998; Akpek et al., 2001; Pacios 
et al., 2004). 
 
 In this study, mycobacterial infections by culture methods comprised 62% 
Mycobacterium tuberculosis (MTB) and 38% Myobacterium avium intracellulare 
(MA). In a study of patients from Chris Hanni Baragwanath Hospital, 29 positive 
blood cultures comprised 86%  MTB and 14% MA (Karstaedt et al., 2001). In 
another South African study of blood culture, 23 out of 71 patients were found to 
be culture positive; 16 out of 23 (70%) had MTB and 7 out of 23 (30%) had MA 
(von Gottberg et al., 2001). 
 
In a study conducted in Kenya using sputum samples,  of the 490 positive 
cultures, 486 (99%) were identified as MTB  (Kivihya-Ndugga, L. et al., 2004). In 
another Kenyan study (Gilks et al., 1995) mycobacterial blood culture yielded 23% 
MTB and 6% MA. 
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In Malawi in a study of 173 patients presenting with HIV infection and fever 
20/173 (12%) were diagnosed with MTB and only one (0.5%) was diagnosed with 
MA on blood culture (Archibald et al., 2000). 
In a Mexican study using sputum, urine, bone marrow aspirates, blood, biopsies of 
lymph nodes, pleura, larynx, bone or skin all the culture results yielded MTB 
(Escobedo-Jaimes et al., 2003).  
In a Spanish study blood and bone marrow aspirate cultures revealed 39% MTB 
and 61% MA (Pacios et al., 2004). A study in Boston (Akpek et al., 2001) a culture 
positivity  of bone marrow, blood, sputum or bronchoaveolar lavage revealed 
25/56 (57%) MA and 5/56 (9%) MTB. 
In a study to detect mycobacteria in bone marrow during  the investigation of 
pyrexia of unknown origin  at St Mary’s Hospital in London (Riley et al., 1995) 
bone marrow cultures of HIV positive patients revealed 82.3% MA, 9.8% MTB. 
The rest was made up of MK and Mycobacterium xenopi. 
In a study by Marques et al., (2000) in USA 27 patients had mycobacterial 
infection detected by blood and/or bone marrow culture. Twenty-five of 27 (94%) 
were MA and 2 of 27 (7%) were MTB. In another study in USA by Keiser et al., 
(1997) 30 cultures of bone marrow aspirates revealed 22 (73%) MA, 1(3%) MTB 
and the remaining 24% comprised histoplasma and aspergillus. 
 
In this study MTB was the predominant mycobacterial species. The prevalence of 
MA in this study is lower than the prevalence reported in UK , USA and Europe 
(Riley et al., 1995; Keiser et al., 1997; Marques et al., 2000; Akpek et al., 2001). 
However, the prevalence is higher than the prevalence reported from other African 
 57
countries (Morrissey et al., 1992; Gilks et al., 1995; Archibald et al., 2000; Kivihya-
Ndugga, L. et al., 2004). 
 
The relative rarity of disseminated MA in developing countries despite its high 
frequency of isolation  from soil and water (Morrissey et al., 1992) was attributed 
to several factors. Exposures to MA in the environment or water supply might be 
less common than in developed countries due to differences in behaviour or in 
water supply systems.  For example, potable hot water was identified as one 
source of MA infection in USA, and that hot water was not widely available  in 
developing countries (von Reyn et al., 1994). Poor patients in developing countries 
might be dying from more virulent infections before they were 
immmunosuppressed enough for MA to develop (Gilks et al., 1995). Patients with 
latent tuberculosis for example, were likely to reactivate this mycobacterial 
infection before they reached the low CD4 count associated with susceptibility to 
MA. Alternatively, prior or continued exposure to MTB or non tuberculous 
mycobacteria might be eliciting or boosting a broad antimycobacterial immunity, 
which remained effective against MA even in advanced HIV infection (Gilks et al., 
1995). 
 
In contrast with the studies from sub-Saharan countries such as Kenya and Malawi 
showing MTB as common and MA as relatively uncommon this study suggested 
that MTB and MA are relatively common in HIV-infected patients in South Africa. 
These findings were similar to those found in a study of febrile adult (≥15 years 
old) HIV-infected patients  in Bangkok (Archibald et al., 1999). 
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The possible explanation for relatively common MA infection in South Africa may 
be that South  Africa being a middle income nation with  unusually high level of 
income inequality (Harling et al., 2008), has better health services than other 
resource-poor sub-Saharan countries. Also exposures to MA in the environment or 
water supply might be more common than in other sub-Saharan countries as  
potable hot water was identified as one source of MA infection in USA (von Reyn 
et al., 1994), and  hot water was likely more widely available  in South Africa than 
in other sub-Saharan countries.  
 
Disseminated mycobacterial infections caused by Mycobacterium tuberculosis and 
Mycobacterium avium are common complications of late stage human 
immunodeficiency virus infection, and the disease diagnosis remains a critical 
problem for clinicians (Gazzola et al., 2008). Multiple methods of diagnosing 
disseminated bacterial infections are crucial. The use of culture alone could have 
missed 9 out of 26 (35%) culture negative patients who were positive for 
granulomata, ZN staining and /or PCR. 
  
4.1.2 Bone marrow trephine biopsy granulomata 
 
In this study the presence of granulomata had a high sensitivity (97.1%) of 
detecting patients who had mycobacterial infection by culture method. This finding 
differed greatly with two studies which reported a 24.4%  granulomata in culture 
positive patients (Riley et al., 1995) and 9 (33.3%) granulomata in 27 patients 
with mycobacterial infection detected by culture (Marques et al., 2000). This study 
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however concurred with the Japanese study which demonstrated granulomata in 
all the cases of miliary tuberculosis (Kinoshita et al., 1994). 
The results of this study suggest that the presence of granulomata can be used as 
a screening test, however the specificity is low (23.1%). Keiser et al., (1997) 
reported that pathologic findings of the bone marrow trephine biopsies were 
predictive of disseminated infections. Patients with granulomata were 4.1 times 
more likely to have a positive culture than those without granulomata. 
 
Despite granulomata showing high sensitivity for mycobacterial infection many 
disorders have been implicated in the pathogenesis of bone marrow granulomata; 
but they are not specific and do not usually show characteristic features that typify 
a specific diagnosis (Eid et al., 1996). However some specific pathologic findings 
can point toward certain diagnoses, for instance, caseation in tuberculosis, Reed-
Sternberg cells in Hodgkin’s lymphoma and poorly organised granulomata in HIV 
infection (Eid et al., 1996). In this study no caseations were present in the 
trephine biopsies and many trephine biopsies had poorly formed or loosely 
organised granulomata. The differential diagnoses of bone marrow granulomata 
include: 
• Malignant neoplasms – most being non-Hodgkin’s and Hodgkin’s 
lymphoma. The granulomata in patients with lymphoma can be due to the 
invasion of the bone marrow or, more frequently, a non-specific 
immunologic change due to cancer; 
• Infectious causes such as bacterial, viral, fungal and parasitic infections. 
Viral causes include Epstein-Barr virus (EBV), cytomegalovirus (CMV) and 
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HIV. Disseminated fungal infections of histoplasmosis are common in 
immunocompromised patients; 
• Sarcoidosis; 
• Drugs such as sulphonamide and procainamide  
• Connective tissue diseases (Eid et al., 1996). 
 
In this study 20 out of 26 mycobacterial culture negative patients had 
granulomata in their bone marrow trephine biopsies. The granulomata might be 
due to other infectious causes other than mycobacteria. Most of these study 
subjects were severely immunocompromised and therefore quite susceptible to 
infections such as CMV, EBV and histoplasmosis. None of the subjects were 
diagnosed with malignant neoplasms. One out of 34 mycobacterial culture positive 
patients and 6 out of 26 mycobacterial culture negative patients did not have 
granulomata in their bone marrow trephine biopsy. These granulomata might be 
truly absent or might have been missed as in HIV infection granulomata are  
poorly organised (Eid et al., 1996). The examination of several cores of bone 
marrow trephine biopsy is sometimes required to detect granulomata.  
 
4.1.3 Bone marrow trephine biopsy Ziehl-Neelsen stain 
 
Bone marrow trephine biopsy ZN stain gave a sensitivity of 64.7% and a specificity 
of 57.7%. This sensitivity was higher than that reported by Marques et al., (2000) 
who demonstrated acid-fast bacilli in only 7 of 25 patients (28%) infected with MA 
and in 1 patient (50%) infected with MTB. This result suggests that ZN staining of 
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bone marrow trephine biopsy can be of high clinical utility when disseminated 
mycobacterial infection is suspected. 
 4.1.4 Bone marrow trephine biopsy Ziehl-Neelsen stain vs. Bone marrow 
trephine biopsy granulomata 
 
The relationship between bone marrow trephine biopsy ZN acid-fast bacilli 
positivity and bone marrow trephine biopsy granulomata was explored. This study 
found that 97% of all trephine biopsies that stained positive for acid-fast bacilli 
had granulomata. This study finding concurred with Riley et al., (1995), who 
reported seeing acid-fast bacilli only in the presence of granulomata. This finding, 
however, differed from that of Bishburg et al., (1986) who observed that 
granulomata were absent in any of the infected bone marrow specimens despite 
the abundance of mycobacteria on histological examination. 
In the light of this study, doing ZN stain without seeing granulomata on bone 
marrow trephine biopsy is wasteful. Ziehl-Neelsen stain for mycobacteria should 
be used only if granulomata are seen on the trephine biopsy. 
 
4.1.5 CD4 Count 
 
The patients in this study had a low mean CD4 count of 67.7x106/l. The patients 
with Mycobacterium avium intracellulare had a much lower mean CD4 count than 
patients with Mycobacterium tuberculosis (19.7X106/l vs. 67.6x106/l). These 
findings are similar to those reported by Marques et al., (2000) in USA who 
observed that the patients with MA infection had a much lower mean CD4 count 
than those with MTB. 
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4.1.6 Mycobacterial DNA PCR 
 
The real-Time PCR of mycobacterial DNA in this study when compared to 
mycobacterial culture as gold standard showed a low sensitivity of 50%. 
This sensitivity is comparable to those published in literature, for example in the  
Italian study of TB PCR (Gazzola et al., 2008),  the sensitivities of blood and bone 
marrow aspirate samples were 53% and  60% respectively. 
A study in Zambia using sputum specimens, an ‘in house’ TB PCR and a gold 
standard incorporating both microbiological and clinical data showed 55% 
sensitivity (Kambashi et al., 2001). These investigators concluded that the low 
PCR sensitivity precluded its use as a tool in the routine diagnosis of pulmonary 
tuberculosis. The above two studies are different from the two Kenyan studies. 
One of them using sputum samples and culture as a gold standard, the sensitivity 
of TB PCR with at least one of the 3 samples was 93%  (van Cleeff et al., 2005). 
In another study using sputum samples and culture as a gold standard a 
sensitivity and specificity of 93% and 84% respectively were reported (Kivihya-
Ndugga, L. et al., 2004). 
 
In an Indian study using clinical samples, clinical, radiological and 
histopathological evidence of TB including clinical response to antitubercular 
treatment as a gold standard  PCR  was reported to have the sensitivity and 
specificity of 74.4% and 97.3% respectively (Negi et al., 2005). 
In another Indian study, using bone marrow aspirates for mycobacterial DNA PCR 
and clinical categories: definite tuberculosis, probable tuberculosis and possible 
tuberculosis as a gold standard obtained the following PCR sensitivities: 62.5% in 
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definite diagnosis, 40% in probable diagnosis of tuberculosis and 12% in possible 
diagnosis (Singh et al., 2006). 
Using acid fast smear and culture as a gold standard, the PCR of extra pulmonary 
samples showed a sensitivity of 90% (Sekar et al., 2008). Using non respiratory 
clinical samples, and culture and final clinical diagnosis as a gold standard  the 
PCR sensitivity and specificity of 77.7% and 98.7% respectively were reported 
(Gamboa et al., 1998). 
These studies have reported different ranges of sensitivities and specificities 
depending on the gold standard and other methodological factors used. Although 
investigators had previously reported that the choice of PCR kit was not important, 
but attention to detail with which the whole method was conducted (Noordhoek et 
al., 1996), there is  need for standardisation of reagents and methodology, and 
particularly standardisation of the gold standard (Kivihya-Ndugga, L. et al., 2004). 
 
A recent study looked at the performance characteristics of the Cobas Amplicor 
MTB test and RT-PCR and with culture as a gold standard different sensitivities 
were obtained. The Cobas Amplicor had a sensitivity of 88.9% and the RT-PCR 
had a sensitivity of 66.7% (Desikan et al., 2009). The investigators concluded that 
the observed variation might be due to genotypic differences, and that a change 
in geographical region might alter the reported performance characteristics of 
some commercially available PCR tests.  
The 50% sensitivity obtained in this study although in agreement with other 
studies is low for effective use as a tool in the diagnosis of mycobacterial 
infections. This low sensitivity may be due to several factors. The PCR 
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amplification kit as per manufacturer’s instructions was for use on sputum 
samples. This study however adapted the use of the kit from sputum samples to 
bone marrow aspirates, and this might have contributed to the low sensitivity. The 
low sensitivity of PCR could also be due to the absence of organisms in the small 
amount of bone marrow aspirates smeared on a slide due to non uniform 
distribution of micro organism in the clinical samples. 
The presence of PCR reaction inhibitors contributing to low sensitivity was unlikely 
because each sample was run with an internal control which had to be co 
amplified for the run to be deemed successful. Internal controls for each run for 
this study were co amplified as shown in figures 3.3 and 3.4. 
 
Mycobacterial DNA was amplified in 7 of 26 (23%) of culture negative samples. 
Cross-contamination was not a problem, since all samples were run with a 
negative control which remained negative during each run. The PCR mix for 
LightCycler Mycobacterium Detection Kit contained Uracil-DNA Glycosylase which 
minimised the risks of contamination from previous PCR runs. 
Two out of 7 patients who had a positive PCR (study numbers 2 and 13) had 
negative ZN stain on bone marrow trephine biopsy, while 5 out of 7 patients 
(patient number 11, 12, 16, 65 and 70) all had disseminated acid-fast bacilli on 
bone marrow trephine biopsy.  Patient 65 was also documented to have a positive 
sputum smear for AFB. The positive PCR might indicate the presence of non-viable 
AFB, particularly in patients with a history of mycobacterial infection in the past. 
However a negative AFB culture could not entirely exclude a clinical diagnosis of 
mycobacterial infection particularly in patients with clinical and radiological 
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features suggestive of mycobacterial infection. Although mycobacterial DNA PCR 
has been shown to be rapid, sensitive and specific diagnostic assay, the results 
should be interpreted with care in the clinical setting (Cheng et al., 2004). 
4.2 Study limitations 
 
There are a number of limitations to this study. Firstly the number of study 
patients was small (n=60). Secondly the PCR amplification kit as per 
manufacturer’s instructions was for use on sputum samples. This study however 
adapted the use of the kit from sputum samples to bone marrow aspirates.  
 
This study would have been strengthened by the addition of clinical presentation 
of patients. This was not done because most of the bone marrow aspirates/ 
trephine biopsy request forms did not contain full clinical information on the 
patients. Obtaining full clinical information might have allowed for clearer 
definitions of indications for bone marrow aspirate/ trephine in HIV positive 
patients in our environment.  
 
The study did not evaluate whether tuberculosis was diagnosed by any other 
means such as sputum smears or sputum cultures.  
 
The study did not assess the cost of culture, ZN staining, histological examination 
of trephine biopsy and the PCR. The assessment of the cost could provide some 
insight into the most cost-effective means of investigating this group of patients, 
as the costs of tests are a major issue in South Africa. 
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4.3 CONCLUDING REMARKS 
 
In this study Mycobacterium tuberculosis was a predominant species. The 
prevalence of Mycobacterium avium was higher than that reported in other African 
countries but still lower than that reported in the United States and Europe. 
Granulomata had a highest sensitivity of detecting patients who had mycobacterial 
infection. Granulomata could be used as a screening test for mycobacterial 
infections, and when present majority of them stained positive for acid-fast bacilli. 
It might be unnecessary to use ZN stains for mycobacteria if no granulomata were 
seen on the trephine biopsy. This study showed also that Ziehl-Neelsen stain of 
bone marrow trephine biopsy was quite sensitive in detecting those with 
mycobacterial infection. 
In resource-poor countries where culture methods are not readily available, 
histological examination and Ziehl-Neelsen staining of bone marrow trephine 
biopsy may offer a highly diagnostic tool in the diagnosis of disseminated 
tuberculosis. 
The sensitivity of mycobacterial DNA PCR was low for adoption of PCR as a sole 
tool in the diagnosis of mycobacterial infections. 
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